Chinese Pulmonary Arterial Hypertension Patient Outcomes on Selexipag Triple Therapy

153 patients from a single-center retrospective study at Qilu Hospital of Shandong University from February 2022 to November 2023 were analyzed for safety and efficacy of selexipag-based triple therapy. The dataset includes non-invasive risk assessment scores, echocardiogram parameters, and clinical data, showing significant improvements in exercise capacity and right heart structure after a median 29-week treatment period. The study, authored by Xiaopei Cui and last updated in May 2026, compares initial versus early sequential triple combination therapy.

Use Cases

• Compare treatment efficacy between initial and sequential triple therapy based on WHO functional class and 6-minute walk distance.
• Analyze the relationship between selexipag treatment duration and changes in right atrial area and ventricle diameter.
• Model risk stratification improvement using the French pulmonary hypertension network non-invasive risk assessment criteria.
• Assess the impact of triple therapy on NT-proBNP levels as a biomarker for disease progression.

Strengths

• Includes data from 153 patients for safety analysis and 146 for efficacy analysis, providing a substantial cohort.
• Reports specific, statistically significant outcome measures, including a hazard ratio of 0.177 for disease progression.
• Contains longitudinal data with an average follow-up period of 33 ± 10 months, allowing for progression analysis.
• Uses established clinical metrics like WHO functional class, 6MWD, NT-proBNP, and echocardiogram parameters.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for large-scale modeling.
• Data is from a single-center study (Qilu Hospital), which may limit generalizability.

Provenance

Source

Qilu Hospital of Shandong University

Collection Method

Single-center, retrospective study.

Time Range

February 2022 to November 2023 for patient inclusion, with a 33-month average follow-up.

Freshness

Last updated 2026-05-21 05:44:04; freshness should be verified.

Geography

China (specifically Chinese patients at a hospital in Shandong).